CAU
ABCL icon

Caxton Associates (UK)’s AbCellera Biologics ABCL Stock Holding History

Caxton Associates (UK)’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-357,506
Closed -$1.8M – 755
2025
Q3 		$1.8M Buy
+357,506
New +$1.58M 0.04% 221

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caxton Associates (UK)'s ABCL Position: Q4 2025 in Review

Caxton Associates (UK) sold out of AbCellera Biologics (ABCL) in Q4 2025, closing a stake of 357,506 shares — an estimated $1.8M sold.

Caxton Associates (UK) first reported a position in ABCL in Q3 2025 and held it in 1 quarter. The position peaked at $1.8M in Q3 2025. 144 funds tracked by Wall St. Rank hold ABCL as of Q4 2025.

  • Caxton Associates (UK) reported no remaining AbCellera Biologics position as of Q4 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 357,506 AbCellera Biologics shares in Q4 2025, an estimated $1.8M.
  • Caxton Associates (UK) first reported a position in AbCellera Biologics in Q3 2025 and held it in 1 quarter.
  • Caxton Associates (UK)'s AbCellera Biologics position peaked at $1.8M in Q3 2025.
  • 144 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2025.

Based on Caxton Associates (UK)'s 13F filing for Q4 2025, filed 13 Feb 2026.